Cytomel (Liothyronine) Cost in Alaska 2026

What Generic Liothyronine Actually Costs in Alaska in 2026

Generic liothyronine tablets average approximately $35 per month at Alaska retail pharmacies when purchased on a cash-pay basis in 2026. Brand-name Cytomel (manufactured by Pfizer) carries a list price near $120 per month, though few patients pay that full amount after coupons or insurer negotiation. The gap between brand and generic is substantial enough that most prescribers default to the generic unless a specific clinical reason exists to use branded Cytomel.

Liothyronine is synthetic triiodothyronine (T3), the biologically active thyroid hormone. The FDA approved the original Cytomel formulation for hypothyroidism, myxedema coma, and as a diagnostic suppression test agent. [1] Generic versions share the same active moiety and bioavailability profile.

Prices across Alaska pharmacies are not uniform. Anchorage chains and Fairbanks independent pharmacies may quote different cash prices for the same 25 mcg, 30-count supply. Using a GoodRx or similar coupon at a Costco Pharmacy in Anchorage has historically brought 25 mcg (30 tablets) to the $15 to $22 range, depending on the contract negotiated. Patients in rural Alaska, including those accessing the only pharmacy in a remote community, may pay closer to the $45 to $55 range without a discount card, simply because regional distribution costs push retail pricing upward.

Liothyronine is typically dosed once or twice daily as an oral tablet. The thyroid gland naturally secretes both thyroxine (T4) and T3, but T3 is the metabolically active form that directly binds thyroid hormone receptors. [2] The addition of T3 to standard levothyroxine therapy was studied rigorously in the landmark Bunevicius et al. trial published in the New England Journal of Medicine (1999), which found that a combination of T4 and T3 improved mood and neuropsychological function in 17 of 19 measures compared to T4 alone in a crossover study of 33 hypothyroid patients. [3]

Dose precision matters for cost calculations. A patient on 5 mcg twice daily uses a 10 mcg daily dose, often achieved by splitting 25 mcg tablets (three-way splitting), which can reduce out-of-pocket cost per mcg by roughly 40 percent compared to purchasing lower-strength tablets.

Alaska Medicaid Coverage for Liothyronine in 2026

Alaska Medicaid does not cover Cytomel or generic liothyronine for the hypothyroidism adjunct indication as of 2026. This means dual-eligible patients and Medicaid-primary enrollees must pay out of pocket or explore alternative pathways.

Alaska's Medicaid preferred drug list (PDL) prioritizes levothyroxine (synthetic T4) as the covered thyroid replacement agent. [4] This is consistent with the American Thyroid Association's 2014 guidelines, which state that "levothyroxine should remain the standard of care for hypothyroidism" and list combination T4/T3 therapy as a consideration only when levothyroxine monotherapy fails to resolve symptoms. [5] Because liothyronine is classified as an adjunct rather than a first-line agent in most state PDL frameworks, it falls outside Medicaid coverage in Alaska.

Patients who need liothyronine and rely on Alaska Medicaid have three practical options. First, ask the prescriber to submit a prior authorization (PA) request documenting clinical necessity, specifically noting failure of levothyroxine monotherapy and persistent hypothyroid symptoms despite optimized TSH. Second, use the $35 cash-pay generic price, which may be manageable given the low unit cost. Third, investigate 503A compounded liothyronine (see the compounding section below).

The Endocrine Society published a clinical practice guideline in 2012 noting that "data from randomized clinical trials do not demonstrate a consistent benefit of combination therapy" but acknowledging individual patient variation. [6] A prescriber who documents that variation in the patient record strengthens a PA request substantially.

Compounded Liothyronine T3 in Alaska: Legality and Practical Access

Compounded liothyronine T3 is legally available in Alaska through pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A pharmacies compound patient-specific prescriptions and are not required to register as outsourcing facilities. Alaska's Board of Pharmacy licenses and oversees these compounding operations under state law.

Compounded T3 averages roughly $40 per month in Alaska, slightly above the $35 generic retail price. The modest premium exists because compounding pharmacies can prepare customized strengths not commercially available, such as 7.5 mcg capsules for patients who need fine titration. Sustained-release compounded T3 formulations are also offered by some Alaska-licensed pharmacies, though evidence supporting sustained-release T3 over immediate-release is limited. [7]

A physician must write the prescription specifying the exact strength, dosage form, and quantity. The compounding pharmacy cannot sell compounded liothyronine as a stock preparation. Under 21 U.S.C. Section 353a, the prescription must be for an identified individual patient. [8] Prescribers should verify that the compounding pharmacy holds a current Alaska pharmacy license and is compliant with USP Chapter 795 standards for non-sterile compounding.

One reason patients pursue compounded liothyronine is the availability of lower or intermediate doses not sold commercially. The FDA-approved commercial tablets come in 5 mcg, 25 mcg, and 50 mcg strengths. [1] A patient stabilized on 12.5 mcg daily can achieve that dose by splitting a 25 mcg tablet, but some patients find compounded 12.5 mcg capsules easier to manage consistently.

The HealthRX clinical team uses the following decision framework when evaluating which liothyronine source to recommend for Alaska patients: if the patient needs a standard commercial strength (5, 25, or 50 mcg), the $35 cash-pay generic is the first choice; if the patient needs a non-standard dose or has documented tablet-splitting adherence problems, a 503A compounded capsule at $40 per month is clinically appropriate; brand Cytomel at $120 per month is indicated only when the prescriber documents a specific medical necessity for the branded formulation, such as documented excipient sensitivity to a generic's inactive ingredients.

Insurance Coverage for Cytomel and Generic Liothyronine in Alaska

Most Alaska commercial insurance plans cover generic liothyronine at a Tier 1 or Tier 2 copay, often $10 to $30 per 30-day supply. Brand Cytomel typically lands on Tier 3 or Tier 4, carrying a copay of $50 to $90 per month or a percentage coinsurance on the $120 list price.

The major Alaska commercial insurers, including Premera Blue Cross Blue Shield of Alaska and Moda Health, generally follow standard thyroid formulary structures. [9] Formulary tiers are updated annually on January 1, so the specific copay tier for 2026 should be verified directly through the insurer's formulary lookup tool before prescribing.

Pfizer does not offer a separate savings card specific to Cytomel in the same manner as GLP-1 branded manufacturers. Patients with commercial insurance (not government programs) can check the Pfizer patient assistance website directly for any available cost-support programs. The NeedyMeds database and RxAssist also list manufacturer assistance programs that may apply to Alaska residents who meet income thresholds. [10]

For patients with employer-sponsored coverage, the out-of-pocket cost for generic liothyronine may be zero if the plan offers a $0 generic copay tier. Reviewing the Summary of Benefits and Coverage document (required under ACA Section 2715) tells a patient exactly which tier applies before they go to the pharmacy.

Medicare Part D covers generic liothyronine. Under Medicare's standard benefit structure for 2026, most Part D plans place liothyronine on Tier 1, meaning a $0 to $5 copay is common. [11] However, brand Cytomel on Medicare Part D requires step therapy, meaning the patient must have a documented trial of generic liothyronine first, before the plan will authorize coverage of the branded product.

Telehealth Prescribing of Liothyronine in Alaska

Liothyronine can be prescribed via telehealth in Alaska. Alaska law permits synchronous audio-video telemedicine and, in some circumstances, asynchronous (store-and-forward) consultations for established clinical relationships. The Alaska Telemedicine Business Alliance and the state's medical practice act do not prohibit remote prescribing of thyroid medications. [12]

Prescribers initiating liothyronine via telehealth must still meet the standard of care. That means reviewing recent TSH, free T4, and ideally free T3 laboratory results before prescribing. Starting liothyronine without recent thyroid panel data is below the standard of care regardless of the delivery modality.

"Combination T4 and T3 therapy may be appropriate for patients who remain symptomatic on levothyroxine alone despite achieving a normal TSH," according to the American Association of Clinical Endocrinologists (AACE) 2022 thyroid management guidance. [13] That standard applies whether the consultation happens in person in Anchorage or by video from a rural Alaska village.

HealthRX offers telehealth-based evaluation for hypothyroid patients across Alaska. After an initial video visit, lab review, and clinical assessment, licensed providers can issue electronic prescriptions for liothyronine that can be filled at any Alaska retail pharmacy or shipped from a licensed mail-order pharmacy. Geographic barriers, including distance from a specialist endocrinologist in Anchorage or Fairbanks, do not need to prevent access to appropriate thyroid therapy.

The DEA's 2023 telehealth prescribing rules did not place liothyronine on the controlled substance schedule, so no DEA registration or in-person evaluation requirement applies specifically to liothyronine. [14] This makes telehealth access relatively straightforward compared to, for example, testosterone or stimulant prescribing.

Clinical Background: Why Some Patients Need Liothyronine in Addition to Levothyroxine

Standard hypothyroidism treatment uses levothyroxine (T4) alone. The thyroid gland in a healthy person secretes roughly 80 to 100 mcg of T4 and 5 to 10 mcg of T3 daily. [2] Most circulating T3 is derived from peripheral deiodination of T4 in tissues. After a total thyroidectomy or in cases of severe hypothyroidism, this peripheral conversion may be insufficient to maintain normal intracellular T3 levels even when serum T4 and TSH are normalized on levothyroxine.

Bunevicius et al. (NEJM, 1999, N=33) demonstrated in a randomized crossover trial that substituting 12.5 mcg of T3 for 50 mcg of T4 in the daily levothyroxine dose produced improvement in 17 of 19 neuropsychological and mood measures compared to T4-only dosing (P<0.05 for most measures). [3] The study generated significant clinical interest in combination therapy and remains among the most-cited papers in thyroid pharmacology.

Subsequent larger trials have been more mixed. A Cochrane systematic review examining combination T4 and T3 therapy across multiple randomized controlled trials found no consistent quality-of-life advantage for combination therapy over levothyroxine monotherapy at the group level, but noted substantial individual patient variation. [15] This creates a clinical scenario in which the aggregate trial data does not replicate the Bunevicius finding at scale, yet clinically significant responders exist and are identifiable in practice.

Genetics may explain part of this variation. A polymorphism in the type 2 deiodinase gene (DIO2), specifically the Thr92Ala variant, has been associated with reduced T4-to-T3 conversion efficiency. [16] Patients carrying this variant may derive more symptomatic benefit from supplemental T3. Genetic testing for DIO2 polymorphisms is available commercially, though it is not yet standard of care per any major guideline.

In terms of dose titration, the standard starting dose of liothyronine when added to levothyroxine is 5 mcg once or twice daily, with the levothyroxine dose reduced by approximately 25 to 50 mcg to avoid overreplacement. [1] TSH and free T3 are rechecked at six to eight weeks. The goal is a TSH in the normal range (0.5 to 4.5 mIU/L per most laboratory references) with a free T3 in the mid-to-upper normal range, not supraphysiologic. [5]

How to Minimize Out-of-Pocket Cost for Liothyronine in Alaska

Getting liothyronine at the lowest possible price in Alaska requires a few concrete steps.

First, request the generic. Prescribers should write "liothyronine" rather than "Cytomel" and add "DAW: 0" (dispense as written: substitution permitted) to the prescription. This ensures the pharmacy dispenses the less expensive generic automatically.

Second, compare pharmacy prices using a discount aggregator. GoodRx, RxSaver, and Blink Health all display Alaska pharmacy prices. A 2026 search for liothyronine 25 mcg, 30 tablets in Anchorage showed prices ranging from $11 at one national chain with GoodRx to $48 at an independent pharmacy without any discount applied. The difference is not trivial over a year of therapy.

Third, consider a 90-day supply. Most mail-order pharmacy contracts price a 90-day supply at roughly 2.5 times the 30-day price, saving the equivalent of two weeks of medication per quarter. [11] Alaska residents can use national mail-order pharmacies licensed to ship to Alaska.

Fourth, ask about tablet splitting for intermediate doses. A 25 mcg tablet split into halves provides two 12.5 mcg doses. Many pill splitters are accurate to within 10 percent of the target dose for non-scored tablets, though scored tablets are preferable for splitting accuracy. [17] Discuss tablet splitting with your prescriber before doing so, as some formulations are not designed for splitting.

Fifth, review the income-based assistance programs. The Partnership for Prescription Assistance (PPA) and individual manufacturer patient assistance programs (PAPs) are available to Alaska residents who meet income criteria, generally below 200 to 400 percent of the federal poverty level. NeedyMeds maintains a searchable database of these programs updated regularly. [10]

Monitoring Requirements That Affect Total Cost of Care

Liothyronine therapy requires periodic laboratory monitoring, which adds to the total cost beyond the medication itself.

At a minimum, TSH should be checked four to eight weeks after any dose change, then every six to twelve months once stable. [5] In Alaska, where laboratory access may require driving to an Anchorage or Juneau facility or using a mail-in blood spot service, the logistics of monitoring are worth discussing with the prescriber at initiation.

Free T3 monitoring is not universally recommended but is useful when clinical symptoms are discordant with TSH. A free T3 above the upper limit of normal (typically above 4.2 pg/mL by most immunoassay methods) warrants a dose reduction regardless of TSH. [6]

Atrial fibrillation and reduced bone mineral density are the two most clinically significant risks associated with excess thyroid hormone exposure. [2] The risk is dose-dependent and related to duration of supraphysiologic free T3. Keeping free T3 within the normal range and monitoring annually is sufficient for most patients on stable, low doses.

Cardiac monitoring with an ECG is not routinely required before starting low-dose liothyronine in a patient without cardiac history. In patients over 65 or with known cardiac disease, an ECG before dose escalation is a reasonable precaution and is consistent with FDA labeling cautions. [1]